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AstraZeneca R&D So¨derta¨lje, So¨derta¨lje, SwedenABSTRACT The pharmacology and regulation of Transient Receptor Potential Ankyrin 1 (TRPA1) ion channel activity is intri-
cate due to the physiological function as an integrator of multiple chemical, mechanical, and temperature stimuli as well as differ-
ences in species pharmacology. In this study, we describe and compare the current inhibition efficacy of human TRPA1 on three
different TRPA1 antagonists. We used a homology model of TRPA1 based on Kv1.2 to select pore vestibule residues available
for interaction with ligands entering the vestibule. Site-directed mutation constructs were expressed in Xenopus oocytes and
their functionality and pharmacology assessed to support and improve our homology model. Based on the functional pharma-
cology results we propose an antagonist-binding site in the vestibule of the TRPA1 ion channel. We use the results to describe
the proposed intravestibular ligand-binding site in TRPA1 in detail. Based on the single site substitutions, we designed a human
TRPA1 receptor by substituting several residues in the vestibule and adjacent regions from the rat receptor to address and
explain observed species pharmacology differences. In parallel, the lack of effect on HC-030031 inhibition by the vestibule
substitutions suggests that this molecule interacts with TRPA1 via a binding site not situated in the vestibule.INTRODUCTIONThe nonselective cation channel TRPA1 is the single
member of the ankyrin repeat-rich branch of the transient
receptor potential (TRP) channel family comprising 28
mammalian subunit genes (1). TRPA1 is expressed in
peripheral and central termini of small diameter primary
afferent neurons and the ganglia of these dorsal, trigeminal,
and nodose neurons (2,3). Here it integrates the nociception
of a large variety of different, potentially damaging and nox-
ious stimuli: cold (3–5), electrophilic compounds (2,6,7),
divalent ions (8,9), and mechanical stimulation (10). The
involvement of TRPA1 in noceptive transduction and neuro-
genic inflammation (11,12) is supported by knockout exper-
iments in mice (13,14) and a human gain-of-function
mutation in TRPA1, which causes familial episodic pain
syndrome (15). Despite the convincing target validation of
TRPA1 as a target for analgesic therapy, there are only
a few de novo designed TRPA1 antagonists described in
literature and patents (seven different institutional appli-
cants), and no program has started Phase II recruitment
yet (according to www.clinicaltrial.gov).
TRPA1 activity is regulated by divalent cations, such as
Ca2þ that interact with the EF-hand motive in the
N-terminal region, while Zn2þ binds to single residues
(cysteine and histidine) at both the N- and the C-terminal
(8,9). The influx of Ca2þ ions through the TRPA1 ion
channel increases the open channel probability (9) and
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0006-3495/13/02/0798/9 $2.00Ca2þ-dependent desensitization of TRPA1 (16). Site-
directed mutagenesis studies have revealed the N-terminal
segment as an important interaction site for electrophilic
compounds, which covalently binds to cysteine or lysine
residues in this region (17,18). Several studies have shown
the species specific pharmacology between rodent and
human TRPA1 by new antagonists (19,20) and recently
a more complete species comparison has been published
by Bianchi et al. (21). Chen et al. (19) show by substitution
studies that their electrophilic, thioaminal-containing
compounds, which covalently bind to the upper S6 domain
of TRPA1, block human TRPA1 but activate rat TRPA1.
These structurally analogous compounds are believed to
interact with only a few residues in the S6 transmembrane
domain: S943 and I946 in the human receptor, and the cor-
responding residues A946 and M949 in rats.
The functional TRPA1 ion channel is, like many other
TRP family members, a homotetramer with fourfold
symmetry around a central ion-conducting pore (22). Each
subunit is suggested to have six transmembrane (S1–S6)
segments with intracellular N- and C-termini and the S5
and S6 segments lining the pore (23,24). This overall
topology is similar to the general potassium channel archi-
tecture based on multiple bacterial potassium channel struc-
tures (25). Support for the hypothesis of S5 and S6 lining the
pore can also be drawn from high sequence similarity in S5
and S6 between different TRP channels (26).
The multiple potentiation and activation/inactivation
modes of TRPA1 pose a challenge to the interpretation of
mutagenesis-based structure function studies given the
interdependencies of the various stimuli. Further, the pecu-
liar rodent to human pharmacology species differences posehttp://dx.doi.org/10.1016/j.bpj.2013.01.008
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late preclinical analgesia models to human pain conditions.
At the same time, however, these species differences can
yield clues to the ligand-regulated activity of TRPA1 and
identify putative drugable binding sites. Therefore, drug
discovery and structure-function studies on TRPA1 must
go hand in hand.
In this article, we profile three structurally diverse TRPA1
antagonist compounds: the novel TRPA1 antagonist AZ868
(Compound 16 in Vallin et al. (27)) and the previously
described antagonists A-967079 (28) and HC-030031
(11,29) on the wild-type human TRPA1 receptor, heterolo-
gously expressed in Xenopus oocytes using the two-elec-
trode voltage-clamp method. A homology model of
hTRPA1 was created using the atomic structure with an
open pore activation gate of Kv1.2/Kv2.1 chimera (25) as
structural scaffold. Information from the homology model
was used to select putative compound interacting amino
residues, spanning the upper S6 segment and the lower
part of the pore mouth. Site-directed mutagenesis studies re-
placed the amino residues in hTRPA1 either to alanine
(which changed the functionality of an amino-acid side
chain) or to the corresponding set of amino residues in
rTRPA1. The different TRPA1 constructs were then
analyzed for functionality and pharmacology and compared
with the wild-type hTRPA1 receptor. Based on the func-
tional results and the final iteration of our homology model,
we propose and describe a ligand binding site in the pore
vestibule of hTRPA1.MATERIALS AND METHODS
Molecular biology
The hTRPA1 coding determining sequence (of NM_007332) was subcl-
oned into an oocyte transcription vector containing the 50 and 30 untrans-
lated regions of the Xenopus b-globin gene. hTRPA1 mutants were
generated (M911A, M912A, M911A-M912A, Q940A, L941A, S943A,
F944A, T945A, I946M, F947A, V948A, and I950F) using cassettes of
synthetic DNA fragments (GeneArt, Regensburg, DE). Similarly, in an
additional mutant, amino acids were substituted to the rat equivalents,
respectively (S900T, I905L, E920D, S921A, Y926L, L927F, H933Y,
S937T, A939G, V942I, S943A, I946M, and S985N). The constructs were
sequenced, linearized, and in vitro transcribed (mMESSAGE mMACHINE
T7 Kit; Ambion, Austin, TX). Gel electrophoresis and UV-spectrophotom-
etry were used to confirm high purity and integrity of the mRNA
preparations.Solutions and compounds
Buffers used for two-electrode voltage-clamp experiments were ND96
(NaCl 96 mM, CaCl2 2.4 mM, KCl 2.0 mM, MgCl2 1.0 mM and HEPES
5.0 mM), ND96 Ca2þ-free (ND96 without CaCl2), and ND96, 150 mM
Ca2þ (ND96 with the CaCl2 concentration reduced to 150 mM). The pH
of the buffers was adjusted to 7.5 with NaOH and the solutions were
sterile-filtered before use. Compounds were diluted from 10 mM DMSO
stocks. Zn2þ and compounds to be tested were diluted from stock solutions
in ND96 Ca2þ-free, and then loaded on a 96-well compound plate. The
samples were administered at a volume of 950 mL. For IonWorks (Molec-ular Devices, Sunnyvale, CA) current recordings, we used an intracellular
solution (100 mM K-gluconate, 40 mM KCl, 3.2 mM MgCl2, 5 mM
HEPES, and 3 mM EGTA pH 7.2, osmolarity: 280 mOsmol) and assay
buffer (DPBS buffer supplemented with 0.55 mM D-Glucose and
0.05 mM MgCl2).
AZ868 (Compound 16 in Vallin et al. (27)) was synthesized as previously
described in Vallin et al. (27). A-967079 was synthesized in two steps:
F
OO
F
O
H2N OH
F
N OHStep 1: (E)-1-(4-fluorophenyl)-2-methylpent-1-en-3-one
A solution of 4-fluorobenzaldehyde (1.70 mL, 16.1 mmol) and 3-pentanone
(1.70 mL, 16.1 mmol) in 37% hydrochloric acid (4.0 mL) was heated to re-
flux for 3 h. After cooling to ambient temperature, the mixture was ex-
tracted with ether. The organic layer was washed with water, aqueous
saturated sodium bicarbonate solution, and again with water. After drying
over Na2SO4, the solution was concentrated. The product was purified using
column chromatography (silica gel with an N-heptan/EtOAc gradient) The
resulting product still contained impurities and was recrystallized from
methanol/water 1.5:1 to yield 1.40 g (45%) E)-1-(4-fluorophenyl)-2-meth-
ylpent-1-en-3-one. 1H NMR (500 MHz, DMSO-d6) d ppm 1.03 (t, J ¼
7.25 Hz, 3 H), 1.96 (d, J ¼ 1.26 Hz, 3 H), 2.87 (q, J ¼ 7.25 Hz, 2 H),
7.29 (t, J ¼ 8.83 Hz, 2 H), 7.54–7.61 (m, 2 H), and 7.65 (s, 1 H). MS:
[MþH]þ ¼ 193.2.
Step 2: (1E,3E)-1-(4-fluorophenyl)-2-methylpent-1-en-3-one oxime
Hydroxylamine hydrochloride (0.65 g, 9.4 mmol) was added in one portion
to a solution of (E)-1-(4-fluorophenyl)-2-methylpent-1-en-3-one (1.2 g,
6.2 mmol) in pyridine (15 mL). The obtained reaction mixture was stirred
at ambient temperature for 2 h. The solvent was evaporated and the residue
partitioned between 1 M aqueous hydrochloric acid and ethyl acetate. The
organic phase was washed with water, dried over Na2SO4, filtered, and
concentrated. Two products with the same mass according to LC/MS
were observed. The product mixture was purified using column chromatog-
raphy (silica gel, elution with N-heptan/EtAOAc gradient) and yielded
1.03 g (79%) of the pure major product. 1H NMR (500 MHz, DMSO-d6)
d ppm 1.04 (t, J ¼ 7.57 Hz, 3 H), 1.98 (s, 3 H), 2.60 (q, J ¼ 7.57 Hz,
2 H), 6.89 (s, 1 H), 7.15–7.27 (m, 2 H), 7.36–7.50 (m, 2 H), and 11.08
(s, 1 H). MS: [MþH]þ 208.1.
HC-030031 was purchased from TOSlab (Ekaterinburg, Russia). All
solids were dissolved in DMSO, with a final concentration of 10 mM.Xenopus oocyte preparation
Stage V-IV Xenopus laevis oocytes were obtained defolliculated and ready
for injection from Ecocyte Bioscience (Castrop-Rauxel, Germany). The
oocytes were injected with 3 ng mRNA encoding wild-type or mutant
TRPA1 and then incubated at 18C in ND96 supplemented with gentamicin
(80 mg/mL), penicillin (100 U/mL), and streptomycin (100 mg/mL). Exper-
iments were carried out 3–6 days after injection.Two-electrode voltage-clamp
Experiments were performed using OpusXpress 6000A (Molecular
Devices), a semiautomated system that uses the two-electrode voltage-
clamp technique to record whole-cell currents from eight Xenopus oocytes
in parallel. Glass electrodes were pulled from borosilicate glass capillaries
with inner filament (TW150F-6; World Precision Instruments, Stevenage,
UK) using the electrode puller PP-83 (Narishige, London, UK) and then
filled with 3 M KCl solution. When immersed in perfusion buffer, theBiophysical Journal 104(4) 798–806
800 Klement et al.resistance of the current electrode measured 0.4–2 MU and the voltage
electrode 0.4–10 MU. Oocytes were placed separately in the recording
chambers with a volume of 150 mL and continuously perfused with ND96.
The oocytes were impaled and then clamped at a holding voltage
of – 60 mV (voltage-clamp gain, 2000; voltage-clamp lag, 220 ms; output
gain, 1; filter, 100 Hz) before starting the protocol. Data series with Zn2þ
responses larger than 2 mA or smaller than 0.15 mA were rejected,
because large currents caused unstable responses and currents smaller
than 0.15 mA had too low amplitude/noise ratio for reproducible assessment
of antagonist efficacy. To quantify the effect of the antagonists on
the current amplitude elicited by Zn2þ, the current amplitude in the pres-
ence of antagonist was normalized to the current amplitude in the
absence of antagonist. To get a stable and reproducible agonist response,
Zn2þ activation was repeated three times before coaddition of Zn2þ and
antagonist, followed by at least two repeated Zn2þ additions without antag-
onist to monitor current amplitude stability and reversibility of the tested
compounds.IonWorks QT System (Molecular Dynamics)
Whole-cell currents from CHO cells stably expressing human TRPA1 were
measured on the IonWorks QT System (Molecular Devices). Fresh cell
suspension was prepared immediately before use. Cells were detached
and resuspended in 6–8 mL assay buffer. The final cell suspension volume
was adjusted to ~2,000,000 cells. Preweighed 25–27 mg samples of ampho-
tericin B were dissolved in 0.58 mL of 100% DMSO and further diluted in
175 mL of intracellular solution to a final concentration of 0.1 mg/mL. Test
compounds were serial-diluted in 100% DMSO and subsequently diluted in
assay buffer to a final concentration between 25 mM and 7.9 nM in the patch
plate. Currents were activated by 125 mM cinnamaldehyde. The final
DMSO concentration did not exceed 0.4%. During experiments, the elec-
tronic head and fluidic head of the IonWorks unit were washed with
DPBS between compound additions. Agonist first and then test compound
were applied in a dual application protocol. A depolarizing ramp voltage
protocol from 80 mV to þ100 mV (500 ms) was applied before agonist
addition (Prescan), after agonist addition (Postscan1), and after compound
addition (Postscan2). Agonist activation time was 100 s, compound incuba-
tion time 60 s.Data analysis
The variable studied in the two-electrode voltage-clamp recordings was the
maximum peak amplitude of the current responses measured in mA. Leak
subtraction was performed in the software CLAMPFIT 9.2 (Molecular
Devices) before the data were transferred to the software GRAPHPAD
PRISM 5 (GraphPad Software, La Jolla, CA) for further analysis. Unless
otherwise indicated, calculated data for each compound are presented as
mean blocking effect (%) mean 5 SE. For the IonWorks experiments,
the metric was set to find the mean peak current at 80 and þ100 mV,
respectively, in the voltage ramp. The mean offset current at 0 mV was sub-
tracted from the mean peak currents yielding the absolute difference. The
raw metric values at80 andþ100 mV were used to calculate % inhibitory
effect at each compound concentration ratio as follows:
% of Inhibition ¼

1 ðPostscan2 PrescanÞðPostscan1 PrescanÞ

 100:
For concentration-response curves, data were analyzed by nonlinear regres-
sion analysis with variable slope using GRAPHPAD PRISM ver. 6.0 for
Windows (GraphPad Software) using the equation
Y ¼ Bottomþ ðTop BottomÞð1þ 10^ððLogIC50 XÞ  HillSlopeÞÞ :Biophysical Journal 104(4) 798–806Statistical significance was evaluated using a one-way ANOVA nonpara-
metric Krauskal-Wallis test, and p values < 0.05 (95% confidence level)
were considered statistically significant.Homology models
The amino-acid sequences of human and rat TRPA1 were retrieved from the
SWISS-PROT Protein Sequence Data Bank (entries O75762 and Q6RI86).
The Kv1.2 x-ray structure used as a template in modeling was retrieved
from the Protein Data Bank (PDB:2R9R). The sequence alignment was per-
formed in the software PRIME (Ver. 3.0; Schro¨dinger, New York, NY) with
subsequent manual adjustments. The homology modeling and energy mini-
mization were performed using MAESTRO molecular modeling software
(ver. 9.2; Schro¨dinger). Energy minimization procedure was performed in
a stepwise fashion and performed both with and without ligand present in
the pore region. The calculations were performed ignoring solvent interac-
tions, and the force field used was MMFF as implemented in MAESTRO.
Homology modeling was performed using the PRIME module in
MAESTRO. Rotamers from conserved residues were retained whereas
other residues were built and energy-minimized. Evaluation of the model
was performed by Ramachandran plot and protein reports from
MAESTRO. Visualization and characterization of the pore region binding
site was done using the SiteMap module in MAESTRO (SiteMap ver.
2.5; Schro¨dinger). Docking of ligands to the channel pore region was
performed with the GLIDE module (ver. 5.7; Schro¨dinger). Selection of
most possible ligand pose was done by a combination of docking score
results and visual inspection.RESULTS
To examine which TRPA1 residues that are of importance
for ligand binding, we selected amino-acid substitutions
based on several initially prepared homology models. The
homology models of the rat TRPA1 and human TRPA1
were constructed with a Kv1.2 structure as a template.
Alignment and models were then revised according to the
results of the mutation studies. The resulting alignment
shows that Kv1.2 and TRPA1 share a sequence identity of
only 11% in the S5–S6 region. Several possible alignments
have been proposed (19,30), but referring to our substitution
results, we suggest an alignment as shown (Fig. 1). After
building the final rat and human homology models conform-
ing to the highest degree with the mutation experiments, we
energy-minimized those in a stepwise fashion. The overall
conformations of the structures were maintained properly
during this procedure. There were no obvious differences
between structures with ligand docked before or after
energy minimization, suggesting that the model pore region
is stable.
AZ868 and A-967079 are docked in the human TRPA1
model, showing possible interactions with side chains of
S6 amino-acid residues and residues corresponding to the
selectivity filter (Fig. 2). For clarity, only two of the four
subunits are displayed, and only the substituted residues
are included. Even though the sequence identities are quite
high between species (~80% between human and rat),
several studies and observations in-house suggest that
TRPA1 pharmacology is not conserved between species
(21). Specifically, a number of nonconserved residues
FIGURE 1 Sequence alignment of Kv1.2
(2R9R) with human and rat TRPA1. (Shading is
according to similarity; amino acids with similar
properties have identical tone.)
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pharmacology (19,20).
To test the homology model and examine the importance
of specific amino acids for ligand binding in the proposed S6
region and selectivity filter, we constructed a number of
hTRPA1 constructs with one or more amino-acid substitu-
tions (see Fig. 3 and the Materials and Methods for
a complete list of mutations made). To explore the putative
species difference, we also constructed a rat TRPA1
homology model from the human TRPA1 model. We then
substituted all residues which differed between the rat and
human receptor to construct a human receptor with the
differing rat residues in the S5–S6 linker, the selectivity
filter, and S6 (Fig. 3, right).
To assess the pharmacological effect of the substitutions
(shown in Fig. 3), we developed a functional assay
using two-electrode voltage-clamping of Xenopus oocytes
injected with mRNA coding for the substituted and wild-
type TRPA1 channels. We used Zn2þ as agonist, as it has
been shown to be potent and activate TRPA1 channels by
a noncovalent and fully reversible fashion (8). Further
Zn2þ alone does not evoke currents in uninjected oocytes
(L. Eisele, G. Klement, and M. Dabrowski, unpublished).To avoid desensitization of the TRPA1 current, Ca2þ was
excluded during antagonist application and from the wash
buffer used for perfusion immediately before and after
antagonist application. However, between ligand additions,
the oocytes were perfused with a Ca2þ-containing buffer
(ND96, 150 mM Ca2þ), because a complete exclusion of
Ca2þ proved to cause unstable current responses and
rapidly deteriorating oocyte integrity. The complete assay
protocol, with details of perfusion and buffers, is illustrated
in Fig. 4, A and B.
During characterization of the substituted and wild-type
channels, we noted that assay stability was compromised
by current amplitudes above 1 mA. Despite the careful appli-
cation protocol, avoiding Ca2þ during agonist presence, it
was not possible to obtain concentration response curves
for Zn2þ due to desensitization and destabilization of the
oocytes seen at larger current amplitudes. Thus, in lieu of
using a fixed Zn2þ concentration based on a concentration
response current activation curve, the Zn2þ concentration
was adjusted in each experiment to suit the level of expres-
sion, oocyte condition, and the difference in Zn2þ sensitivity
between substituted channels. Typical Zn2þ concentration
ranged between 2 and 7 mM. Representative current tracesFIGURE 2 Docking poses of AZ868 and
A-967079 in the pore region of TRPA1 according
to the homology model prediction. Structures of
AZ868 and A-967079 are shown in the panels
below the docking poses.
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FIGURE 3 (Left) Illustrating the selectivity filter, S5–S6 linker, and S6 fold according to the homology model. The single and double substitutions studied
are shown at predicted positions on the backbone fold (solid strand). (Right) Illustrating the complete construct with the 12 rat residues substituted in the
human receptor replacing human residues with the corresponding rat residues at predicted positions according to the homology model.
802 Klement et al.from wild-type and substituted TRPA1 channels are shown
in Fig. 4 C.
Interestingly all substituted channels proved to be func-
tional, as current responses were evoked by application of
Zn2þ. However, some of the substituted constructs yielded
altered characteristics of the ion channel with respect to
current amplitudes, Ca2þ sensitivity, and background activity
(as determined by leak current at 60 mV). Two substitu-
tions, M911A-M912A and F944A, resulted in noticeably
smaller current responses and a lower background activity
compared to wild-type channels. Oocytes expressing
L941A or I950F substituted channels displayed markedly
larger currents upon Zn2þ activation and more depolarized
restingmembrane potentials compared towild-type, suggest-
ing an increased background activity of the substituted chan-
nels. L941A- and I950F-expressing oocytes also responded
strongly to Ca2þ in the wash buffer. The rat-substituted
construct (S900T, I905L, E920D, S921A, Y926L, L927F,
H933Y, S937T, A939G, V942I, S943A, I946M, and
S985N), together with six of the other substitutions
(M911A, Q940A, S943A, T945A, I946M, and V948A), did
not seem to affect the channel properties in these respects.
The profile of the three tested TRPA1 antagonists on
substituted and human wild-type TRPA1 receptors are
shown in Fig. 5. Results are expressed as % remaining
current normalized to the control activation by Zn2þ alone.
The concentration of the three TRPA1 antagonists was
guided by their potencies obtained in the IonWorks assay
(Table 1). We selected concentrations slightly higher
than the IC50 values to generate a large but not complete
inhibition percentage on the wild-type channel (60–80%).
For clarity and statistical significance testing, the resultsBiophysical Journal 104(4) 798–806from the oocyte experiments are summarized in Table 2. It
is evident that the efficacy of AZ868 is largely dependent
on the presence of the methionines at position 911 and
912 in contrast to the A-967079 and HC-030031
compounds.
Reducing the size of the amino-acid side chain by replac-
ing methionine with the smaller side-chain alanine is less
efficacious in coordinating and stabilizing the AZ868 mole-
cule in the vestibule. The rest of the pattern on the
substituted channels is mostly shared between A-967079
and AZ868 except for the L941A and I946M substitutions.
L941A has no effect on AZ868 inhibition but increase the
inhibition efficacy by A-967079 slightly. I946M also
improves A-967079 inhibition but reduces the inhibition
by AZ868. All tested substitutions were without significant
effect on the HC-030031 inhibition efficacy. The largest
effect is seen when we remove the benzene ring of F944,
completely abolishing both AZ868 and A-967079 inhibition
of TRPA1 but having no effect on HC-030031 inhibition.
Interestingly, some effect is seen by substituting the two
neighboring residues at positions 945 and 946 as well.
However, the reduction in inhibition was consistent on
both AZ868 and A-967079 but not significant when tested
in one-way ANOVA. Thus, we observe effect on AZ868
and A-967079 interaction by primarily the side-chain posi-
tions of F944, suggesting access to this position from the
inner vestibule. The last two substitutions, V948A and
I950F, affect AZ868 and A-967079 inhibition in a similar
fashion, reducing the TRPA1 current inhibition by half to
30–40% of the control response.
The observation that HC-030031 inhibition is only
marginally affected by all the substitutions tested leads us
FIGURE 4 (A) One application cycle of the assay illustrating type of
application: buffer type or sample. Flow rate and length of application as
indicated (horizontal bars). (B) Examples of corresponding current traces
from an application cycle and a test application using an antagonist. First
application scale showing buffer changes as in panel A. (Vertical scale
bar) Current amplitude. (Horizontal bar) Timescale for all traces. (C)
Example current traces from control and test application obtained using
the application cycle shown in panels A and B. The current traces are re-
corded from, and comparing, TRPA1 WT; rat residues substituted in to
the human TRPA1 receptor, ratified; and the TRPA1 F944A substitution
in control and with 1 mM AZ868 applied as indicated above the traces.
The scale bars show current amplitude and timecourse for all three receptor
constructs.
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with a different site than AZ868 and A-967079. Finally, we
tested the set of 12 combined substitutions replacing the
human TRPA1 receptor residue with the corresponding
residue from the rat receptor in the proposed extracellular
loop before S6 and along the pore segment of S6. This rat
substitution construct was functionally like the other
described substituted channels, but efficacy of AZ868current inhibition was completely abolished, verifying
the lack of species translation for this compound. Even
A-967079 inhibition efficacy was markedly reduced on
the rat substitution construct, whereas the HC-030031 effect
was unaltered.
Homology models of rat and human TRPA1 were con-
structed with the Kv1.2 structure as a template. Whereas
the sequence identities between the TRP ion channel family
sequences allow for a quite straightforward alignment, the
identity between Kv1.2 and TRPA1 is only 11% in the
S5-S6 region, enabling several different and initially equally
good suggestions for the alignment. However, referring to
our substitution results reported here, we propose the final
alignment as shown in Fig. 1. In favor of this alignment is
the preservation of the positions of P949 and N954 relative
to the template sequence as well as the results from the
substitution functionality test. Interestingly, our homology
model can only dock the active enatiomer of the racemic
compound AZ868 ((27) and M. Svensson, G. Terp, and D.
Weigelt, unpublished), further supporting the homology
based on the alignment in Fig. 1.DISCUSSION
Substitution of individual amino-acid residues can directly
affect the drug binding by changing the affinity due to
changes in the available acceptor and donor pattern or
even larger structural/geometric changes of the binding
site. It could also indicate an interference of the access
pathway of the compound, an allosteric effect, or a modifica-
tion of the channel gating. In this study, we assess the
macroscopic whole-cell current amplitudes and can thus
not dissect the individual contributions to the efficacy of
the antagonists. However, by the methodic substitutions
and comparison with the proposed homology model using
three different ligands, we argue that a ligand binding site
exits in the vestibule of the channel pore of TRPA1.
By carefully adjusting assay conditions to optimize
stability, avoid desensitization and other nonequilibrium
artifacts, and by using a reversible ligand, we conclude
that the differential observations of the compound character-
istics on the mutant and wild-type receptors are indeed
consequences of changes in direct interaction with the
specific residues in the pore vestibule of the TRPA1 channel.
The limitation of this argument is that we model a static
picture of a pore region that we know is very flexible. Until
crystal structures of TRP channels are solved, we are limited
to this interpretation on how the ligands interact in the pore
region, being in best agreement with our mutation results.
The AstraZeneca proprietary compound AZ868 shows an
effect of the M911A and M912A substitutions in contrast to
the lack of effect on A-967079 inhibition. According to
our homology model, these methionines are positioned
close to the selectivity filter and can be reached by
AZ868. The SiteMap module (Schro¨dinger) evaluation,Biophysical Journal 104(4) 798–806
FIGURE 5 Box plot of the mean inhibition percentage of the maximal current amplitude for AZ868 (1 mM), A-967079 (0.2 mM), and HC-030031 (10 mM)
as indicated above each panel. The TRPA1 construct type is listed on the y axis and the level of inhibition scale is shown on the x axis. Wild-type inhibition
percentage is written above the vertical line and the inhibition percentage on the individual substitutions is shown as boxes drawn from the WT level. n ¼ 2–
16 (see Table 2 for tabulated list of inhibition and significance).
804 Klement et al.aiming to describe the size and properties of the pore
binding site, shows possibilities for more elongated ligands
to bind in the pore (exemplified by the AZ868 structure).
Our results show that a hydrophobic part of the AZ868
structure interacts with the top of the inner vestibule defined
by the methionines at positions 911 and 912. This is in
accordance with the SiteMap results, showing a preference
for hydrophobicity at this position. Extending the length
of the A-967079 ligand and thereby allowing the structure
to pick up the methionine interaction could possibly cause
an increase in current inhibition efficacy.
The single most dramatic effect on current inhibition is
seen by removing the benzene ring of F944. Substitution
to the smaller alanine completely abolishes A-967079 and
AZ868 current inhibition of TRPA1. Our hypothesis is
that the channel adapts to ligand binding, leading to p-p
stacking of the aromatic rings. In addition, the adaption to
ligand binding could enable a hydrogen bond between the
ligand and the threonine side chain. Results from the substi-
tution study can then be explained by A-967079 and AZ868
interacting with both T945 and F944 as visualized in Fig. 3.
The observation that lengthening the side chain from isoleu-
cine to methionine at position 946 produces opposite effects
between AZ868 and A-967079, is interesting; it also indi-
cates that the vestibule segment of S6 will adapt to ligand
binding. Similarly, the lack of effect by AZ868 and the
modest increase in efficacy of A-967079 on L941A, furtherTABLE 1 Potencies of the tested compounds measured on
IonWorks (Molecular Dynamics) current-clamped CHO cells
expressing human TRPA1 preactivated by 125 mM
cinnamaldehyde
CHO cell AZ868 A-967079 HC-030031
Clamped @ 80 mV 0.75 0.2 0.085 0.02 6.75 1.6
Clamped @ þ100 mV 0.95 0.2 0.15 0.02 8.15 0.6
Half-maximum inhibition values (IC50) in mM. Data represents mean5 SE
for n ¼ 4–20 concentration response curves.
Biophysical Journal 104(4) 798–806strengthen the hypothesis of smaller ligand induced struc-
tural changes in the vestibule.
The effects on V948A and I950F are similar between
AZ868 and A-967079, suggesting a similar interaction
pattern by these ligands in this end of the vestibule. We
also confirm the human species selectivity of AZ868 is
defined by the S6 residues because substitution of the rat
residues into the human receptor results in complete abol-
ishment of inhibition. In comparison, the reduction in
inhibition efficacy for A-967079 is only 50% (from 60 to
30%), which suggests that A-967079 binds similarly, but
not exactly like AZ868 to this set of residues and does
indeed retain some activity in rats. Finally, we only observe
a very limited effect on the inhibition by HC-030031 sug-
gesting a good species crossover by this compound and
entirely different binding mode compared to A-967079
and AZ868. As none of the substitutions influence the
binding of HC-030031, we conclude that this ligand does
not bind to TRPA1 in the pore region, whereas AZ868
and A-967079 efficacy are determined by direct interactions
with amino acids in the pore vestibule.
The multiple modes of regulation of TRPA1 activity pose
a challenge for structure-function studies in general and
antagonist ligand interaction in particular because antago-
nist potency varies pending the mode of activation. There-
fore, when comparing inhibitors of TRPA1 activity, it is
necessary to weigh-in the mode of activation. The S6 region
was identified as critical for AITC and voltage gating of
TRPA1 using site-directed mutagenesis and a homology
model based on an alignment somewhat different than
ours (30). The alignment is shifted by nine residues relative
to our alignment, and the effect of this is that other residues
are predicted to be exposed to the pore, and thereby sug-
gested available for ligand interactions (30).
Menthol activates human TRPA1 as a full agonist but is
only a partial agonist on murine TRPA1. By comparing
menthol efficacy on chimeras between human and murine
TABLE 2 Inhibition of the maximal current amplitude of the three compounds tested on all substitution constructs made
Constructs AZ868 (1 mM) A-967079 (0.2 mM) HC-030031 (10 mM)
Wild-type 725 2 (n ¼ 7) 605 1 (n ¼ 12) 80 5 2 (n ¼ 14))
M911A/M912A 26 5 2a (n ¼ 10) 615 3 (n ¼ 5) 845 2 (n ¼ 10)
L941A 715 3 (n ¼ 5) 745 4 (n ¼ 3) 815 4 (n ¼ 2)
S943A 695 3 (n ¼ 10) 635 3 (n ¼ 7) 785 1 (n ¼ 6)
F944A 5 5 2a (n ¼ 8) 3 5 2a (n ¼ 16) 755 3 (n ¼ 11)
T945A 455 2 (n ¼ 8) 465 2 (n ¼ 12) 745 2 (n ¼ 10)
I946M 575 4 (n ¼ 10) 675 2 (n ¼ 7) 815 2 (n ¼ 5)
V948A 415 4b (n ¼ 11) 27 5 2c (n ¼ 10) 775 3 (n ¼ 15)
I950F 33 5 2a (n ¼ 13) 365 1 (n ¼ 5) 755 3 (n ¼ 16)
Rat substitutions 3 5 1a (n ¼ 5) 30 5 2c (n ¼ 11) 735 1 (n ¼ 9)
Values are mean5 SE and statistical significance is based on a one-way ANOVA test versus the WT inhibition and significance is given by the p values as
stated.
ap < 0.001.
bp ¼ 0.05–0.01.
cp ¼ 0.01–0.001.
Ligand Binding Site in the TRPA1 Pore 805TRPA1 receptors, Xiao et al. (31) find that S5 is critical in
determining the modulation of TRPA1 by menthol and
several other modulators. One should, however, be careful
when directly comparing molecular ligand- and Zn2þ acti-
vated pharmacology on TRPA1 for antagonists dependent
on the pore regions. These results and ours further
strengthen the suggestion of a flexible pore region but also
the intricate interplay between molecular agonists and
antagonist pharmacology.
In an elegant series of experiments using de novo de-
signed TRPA1 antagonists, Chen et al. (19) identified
a number of residues in the S5–S6 linker and the S6 region
as determining the rat/human species difference, site, and
type of effect (activation/inhibition). When comparing these
data to our findings and homology model, they are some-
what different, particularly the S943 and, to some degree,
I946 results. It is important to note the difference in activa-
tion type: covalent binding at cysteine residues versus Zn2þ
charge-charge interaction and the different functional
readout and Ca2þ influx in nonvoltage-controlled cells
versus voltage-clamp current recordings. Finally, the Chen
study also employs a different set of antagonists than ours
in comparing three structurally different antagonists.
However, it is certainly interesting and somewhat
surprising that the S943 and I946 substitutions abolishes
inhibition by the profiled antagonist CMP1 (19), whereas
we observe no change for A-967079 and AZ868 and only
modest changes of the AZ868 and A-967079 inhibition on
the I946M channel (Fig. 5). This could reflect the different
experimental conditions as stated above, or the fact that
different ligands induce different fits in the flexible pore
vestibule. We favor the interpretation that all these residues
can form part of a somewhat flexible binding site in the pore
vestibule. A further observation supporting a flexible ligand
binding site hypothesis is the reversible pore dilation of
TRPA1 under prolonged activation observed by two groups
(32,33). Both groups show that long AITC applications (tens
of seconds) abolish rectification and uptake of the 629-Dalarge organic cationic dyes YoPro in a concentration-depen-
dent fashion. This further stresses a high degree of structural
flexibility in the extracellular loop between S5 and S6, and
the selectivity filter for S5 and S6.CONCLUSION
We propose the existence of a drugable binding site in the
pore of TRPA1 ion channel vestibule defined by two consec-
utive methionines M911 and M912 from the inner mouth of
the selectivity filter and a stretch of residues in S6 from
L941 to I950. If compounds, which can enter the vestibule
and pick up several of these proposed interactions, can be
designed and synthesized, then it may be possible to design
TRPA1 antagonists with high affinity and selectivity for the
human TRPA1 ion channel. Such ligands hold the promise
of becoming a new analgesic treatment in man.
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